Biohaven Pharma (BHVN) Misses Q4 EPS by 22c, Revenue Beats

Biohaven Pharma (NYSE: BHVN) reported Q4 EPS of ($2.32), $0.22 worse than the analyst estimate of ($2.10). Revenue for the quarter came in at $190 million versus the consensus estimate of $169.78 million.

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Berenberg Starts Brooks Macdonald Group PLC (BRK:LN) at Buy
• RBC Capital Downgrades Bucher Industries AG (BUCN:SW) (BCHHF) to Sector Perform